c-Myc蛋白对三阴性乳腺癌增殖迁移的影响
|
摘要
目的:研究c-Myc蛋白对三阴性乳腺癌增殖迁移的影响.方法:应用shRNA进行慢病毒包装,构建低表达稳转株,再用westernblot验证敲低效果.利用MTT验证c-Myc蛋白对三阴性乳腺癌增殖的作用;应用划痕实验、Transwell Assay证明c-Myc蛋白在肿瘤转移中的影响.结果:在myc基因敲低后,c-Myc蛋白表达量明显降低,增殖能力明显下降,迁移能力变弱.结论:c-Myc蛋白作为原癌基因的翻译产物对三阴性乳腺癌的增殖、迁移具有促进作用.
Objective: To study the effect of c-Myc protein on the proliferation and migration of the triple-negative breast cancer. Methods: shRNA was packaged in lentivirus to construct a low-expression stable transfection strain. Westernblot method was used to verify the knockdown efficiency. The effect of c-Myc protein on the proliferation of triple-negative breast cancer was investigated by MTT method. The effect of c-Myc protein on tumor migration was measured by cell scratch test and Transwell Assay.Results: After the knockdown of myc gene,the expression of c-Myc protein was significantly decreased,the proliferative ability of cancer cells was significantly decreased and the migration ability was weakened. Conclusion: c-Myc protein,as a translation product of proto-oncogene,can promote the proliferation and migration of triple-negative breast cancer.
Objective: To study the effect of c-Myc protein on the proliferation and migration of the triple-negative breast cancer. Methods: shRNA was packaged in lentivirus to construct a low-expression stable transfection strain. Westernblot method was used to verify the knockdown efficiency. The effect of c-Myc protein on the proliferation of triple-negative breast cancer was investigated by MTT method. The effect of c-Myc protein on tumor migration was measured by cell scratch test and Transwell Assay.Results: After the knockdown of myc gene,the expression of c-Myc protein was significantly decreased,the proliferative ability of cancer cells was significantly decreased and the migration ability was weakened. Conclusion: c-Myc protein,as a translation product of proto-oncogene,can promote the proliferation and migration of triple-negative breast cancer.
引文
[1] NAGINI S. Breast cancer:current molecular therapeutic targets and new players[J]. Anticancer Agents Med Chem,2017,17(2):152-163.
[2] DENKERT C,LIEDTKE C,TUTT A,et al. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies[J]. Lancet, 2016, 389(10087):2430.
[3] FALLAH Y,BRUNDAGE J,ALLEGAKOEN P,et al.MYC-Driven Pathways in Breast Cancer Subtypes[J].Biomolecules,2017,7(3):53.
[4]苏冬娜,吴诗品. Smad7修饰的骨髓间充质干细胞通过肝星状细胞Smads信号与MMP-1/TIMP-1平衡的抗肝纤维化机制[J].暨南大学学报(自然科学与医学版),2018,39(6):493-499.SU D N, WU S P. Smad7-modified bone marrow mesenchymal stem cells through the hepatic stellate cells Smads signaling and MMP-1/TIMP-1 balance anti-liver fibrosis mechanism[J]. Journal of Jinan University(Natural Science and Medicine Edition),2018,39(6):493-499.
[5]赵贝,常祺,钱凯,等.新基因FAM172A对人脐静脉内皮细胞增殖和凋亡的影响[J].暨南大学学报(自然科学与医学版),2018,39(4):287-298.ZHAO B,CHANG Q,QIAN K,et al. Effects of new gene FAM172A on proliferation and apoptosis of human umbilical vein endothelial cells[J]. Journal of Jinan University(Natural Science and Medicine),2018,39(4):287-298.
[6] LITTLE C D, NAU M M, CARNEY D N, et al.Amplification and expression of the c-myc oncogene in human lung cancer cell lines[J]. Nature,1983,306(5939):194.
[7] CHI V D,KATHRYN A O D,KAREN I Z,et al. The c-Myc target gene network[J]. Seminars in Cancer Biology,2006,16(4):253-264.
[8] TROP-STEINBERG S,AZAR Y. Is Myc an important biomarker? Myc expression in immune disorders and cancer[J]. The American Journal of the Medical Sciences,2018. 355(1):67-75.
[9] YADAV B S,CHANANA P,JHAMB S. Biomarkers in triple negative breast cancer:A review[J]. World Journal of Clinical Oncology,2015,6(6):252-263.
[10] CONSTANTINOU C,PAPADOJPOULOS S,KARYDA E,et al. Expression and clinical significance of claudin-7,PDL-1,PTEN,c-Kit,c-Met,c-Myc,ALK,CK5/6,CK17,p53,EGFR,Ki67,p63 in triple-negative breast cancer-A single centre prospective observational study[J]. Vivo,2018,32(2):303.
[11]刘德纯,赵云霞,癌基因蛋白c-myc、c-myb、c-erbB-2在乳腺癌组织中的表达[J].中国基层医药,2013,20(5):641-643.LIU D C,ZHAO Y X. Expression of oncogene proteins c-myc,c-myb,c-erbB-2 in breast cancer tissues[J].Chinese Journal of Primary Medicine,2013,20(5):641-643.
[12] BING-JIA C,YAN-LING W,YOSHIMASA T,et al.Small molecules targeting c-Myc oncogene:promising anti-cancer therapeutics[J]. International Journal of Biological Sciences,2014,10(10):1084-1096.
[13] BEDARD M,MALTAIS L,MONTAGNE M,et al. Miz-1 and max compete to engage c-Myc:implication for the mechanism of inhibition of c-Myc transcriptional activity by Miz-1[J]. Proteins-structure Function&Bioinformatics,2017,85(2):199.
[14] KNUDSEN E S,A KATHLEEN M,JORGE F,et al. RB loss contributes to aggressive tumor phenotypes in MYCdriven triple negative breast cancer[J]. Cell Cycle,2015,14(1):109-122.
[15]肖英,程爱兰.细胞骨架在肿瘤侵袭转移中的研究进展[J].中国肿瘤临床,2016,43(22):1007-1011.XIAO Y,CHENG A L. Research progress of cytoskeleton in tumor invasion and metastasis[J]. Chinese Journal of Clinical Oncology,2016,43(22):1007-1011.
[16] ROMAIN L,BARBARA H,EDUARDO M. Cell mixing induced by myc is required for competitive tissue invasion and destruction[J]. Nature,2015,524(7566):476.
[17] WEIN L,LOI S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer(TNBC)[J].Breast,2017,34(supple):S0960977617304952.
[2] DENKERT C,LIEDTKE C,TUTT A,et al. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies[J]. Lancet, 2016, 389(10087):2430.
[3] FALLAH Y,BRUNDAGE J,ALLEGAKOEN P,et al.MYC-Driven Pathways in Breast Cancer Subtypes[J].Biomolecules,2017,7(3):53.
[4]苏冬娜,吴诗品. Smad7修饰的骨髓间充质干细胞通过肝星状细胞Smads信号与MMP-1/TIMP-1平衡的抗肝纤维化机制[J].暨南大学学报(自然科学与医学版),2018,39(6):493-499.SU D N, WU S P. Smad7-modified bone marrow mesenchymal stem cells through the hepatic stellate cells Smads signaling and MMP-1/TIMP-1 balance anti-liver fibrosis mechanism[J]. Journal of Jinan University(Natural Science and Medicine Edition),2018,39(6):493-499.
[5]赵贝,常祺,钱凯,等.新基因FAM172A对人脐静脉内皮细胞增殖和凋亡的影响[J].暨南大学学报(自然科学与医学版),2018,39(4):287-298.ZHAO B,CHANG Q,QIAN K,et al. Effects of new gene FAM172A on proliferation and apoptosis of human umbilical vein endothelial cells[J]. Journal of Jinan University(Natural Science and Medicine),2018,39(4):287-298.
[6] LITTLE C D, NAU M M, CARNEY D N, et al.Amplification and expression of the c-myc oncogene in human lung cancer cell lines[J]. Nature,1983,306(5939):194.
[7] CHI V D,KATHRYN A O D,KAREN I Z,et al. The c-Myc target gene network[J]. Seminars in Cancer Biology,2006,16(4):253-264.
[8] TROP-STEINBERG S,AZAR Y. Is Myc an important biomarker? Myc expression in immune disorders and cancer[J]. The American Journal of the Medical Sciences,2018. 355(1):67-75.
[9] YADAV B S,CHANANA P,JHAMB S. Biomarkers in triple negative breast cancer:A review[J]. World Journal of Clinical Oncology,2015,6(6):252-263.
[10] CONSTANTINOU C,PAPADOJPOULOS S,KARYDA E,et al. Expression and clinical significance of claudin-7,PDL-1,PTEN,c-Kit,c-Met,c-Myc,ALK,CK5/6,CK17,p53,EGFR,Ki67,p63 in triple-negative breast cancer-A single centre prospective observational study[J]. Vivo,2018,32(2):303.
[11]刘德纯,赵云霞,癌基因蛋白c-myc、c-myb、c-erbB-2在乳腺癌组织中的表达[J].中国基层医药,2013,20(5):641-643.LIU D C,ZHAO Y X. Expression of oncogene proteins c-myc,c-myb,c-erbB-2 in breast cancer tissues[J].Chinese Journal of Primary Medicine,2013,20(5):641-643.
[12] BING-JIA C,YAN-LING W,YOSHIMASA T,et al.Small molecules targeting c-Myc oncogene:promising anti-cancer therapeutics[J]. International Journal of Biological Sciences,2014,10(10):1084-1096.
[13] BEDARD M,MALTAIS L,MONTAGNE M,et al. Miz-1 and max compete to engage c-Myc:implication for the mechanism of inhibition of c-Myc transcriptional activity by Miz-1[J]. Proteins-structure Function&Bioinformatics,2017,85(2):199.
[14] KNUDSEN E S,A KATHLEEN M,JORGE F,et al. RB loss contributes to aggressive tumor phenotypes in MYCdriven triple negative breast cancer[J]. Cell Cycle,2015,14(1):109-122.
[15]肖英,程爱兰.细胞骨架在肿瘤侵袭转移中的研究进展[J].中国肿瘤临床,2016,43(22):1007-1011.XIAO Y,CHENG A L. Research progress of cytoskeleton in tumor invasion and metastasis[J]. Chinese Journal of Clinical Oncology,2016,43(22):1007-1011.
[16] ROMAIN L,BARBARA H,EDUARDO M. Cell mixing induced by myc is required for competitive tissue invasion and destruction[J]. Nature,2015,524(7566):476.
[17] WEIN L,LOI S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer(TNBC)[J].Breast,2017,34(supple):S0960977617304952.